Ipratropium
|
|
|
| |
| 3-(3-hydroxy-1-oxo-2-phenylpropoxy)- 8-methyl-8-(1-methylethyl)-, (endo,syn)-(+-)-8-azoniabicyclo(3.2.1)octane | |
| CAS number 60205-81-4, 22254-24-6 (bromide) and 66985-17-9 (bromide) | ATC code R01AX03 and R03BB01 |
| Chemical formula | C20H30NO3 |
| Molecular weight | 350.5 or 430.4 (with bromide) |
| Bioavailability | ? |
| Metabolism | ? |
| Elimination half-life | ? |
| Excretion | ? |
| Pregnancy category | ? |
| Legal status | ? |
| Routes of administration | ? |
Ipratropium is an anticholinergic drug (trade name: Atrovent®) administered by inhalation for the treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion.
Clinical uses
Ipratropium has respiratory effects similar to atropine but since it is poorly absorbed into the blood, it has few side effects (such as tachycardia) at therapeutic doses.
It is available under the trade names Alti-Ipratropium (AltiMed), Apo-Ipravent (Apotex), Atrovent Inhalation Aerosol (Boehringer Ingelheim), Atrovent Inhalation Solution (Boehringer Ingelheim), Atrovent Nasal Spray (Boehringer Ingelheim), Gen-Ipratropium (Genpharm), Novo-Ipramide (Novopharm), Nu-Ipratropium (Nu-Pharm), PMS-Ipratropuim (Pharmascience).
Sources
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4